Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Expected outcomes of therapy

1 evidence topic · 1 source

DRAGON: reported reduction in DDAF lesion growth versus placebo

“35.7%” (opens the source at this quote in a new tab)